PMID- 27123564
OWN - NLM
STAT- MEDLINE
DCOM- 20170626
LR  - 20220331
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 19
IP  - 9
DP  - 2016 Sep
TI  - Cost and economic burden of adverse events associated with metastatic melanoma 
      treatments in five countries.
PG  - 900-12
LID - 10.1080/13696998.2016.1184155 [doi]
AB  - OBJECTIVE: To estimate per-event cost and economic burden associated with 
      managing the most common and/or severe metastatic melanoma (MM) treatment-related 
      adverse events (AEs) in Australia, France, Germany, Italy, and the UK. METHODS: 
      AEs associated with chemotherapy (dacarbazine, paclitaxel, fotemustine), 
      immunotherapy (ipilimumab), and targeted therapy (vemurafenib) were identified by 
      literature review. Medical resource use data associated with managing AEs were 
      collected through two blinded Delphi panel cycles in each of the five countries. 
      Published costs were used to estimate per-event costs and combined with AEs 
      incidence, treatment usage, and MM prevalence to estimate the economic burden for 
      each country. RESULTS: The costliest AEs were grade 3/4 events due to 
      immunotherapy (Australia/France: colitis; UK: diarrhea) and chemotherapy 
      (Germany/Italy: neutropenia/leukopenia). Treatment of AEs specific to 
      chemotherapy (Australia/Germany/Italy/France: neutropenia/leukopenia) and 
      targeted therapy (UK: squamous cell carcinoma) contributed heavily to 
      country-specific economic burden. LIMITATIONS: Economic burden was estimated 
      assuming that each patient experienced an AE only once. In addition, the context 
      of settings was heterogeneous and the number of Delphi panel experts was limited. 
      CONCLUSIONS: Management costs for MM treatment-associated AEs can be substantial. 
      Results could be incorporated in economic models that support reimbursement 
      dossiers. With the availability of newer treatments, establishment of a baseline 
      measure of the economic burden of AEs will be crucial for assessing their impact 
      on patients and regional healthcare systems.
FAU - Vouk, Katja
AU  - Vouk K
AD  - a INC Research GmbH , Munich , Germany ;
FAU - Benter, Ursula
AU  - Benter U
AD  - a INC Research GmbH , Munich , Germany ;
FAU - Amonkar, Mayur M
AU  - Amonkar MM
AD  - b Novartis Pharmaceuticals Corporation , Wayne , PA , USA ;
FAU - Marocco, Alessia
AU  - Marocco A
AD  - c Laser Analytica , Milan , Italy ;
FAU - Stapelkamp, Ceilidh
AU  - Stapelkamp C
AD  - d Novartis Pharmaceuticals , London , UK ;
FAU - Pfersch, Sylvie
AU  - Pfersch S
AD  - e Novartis Pharma S.A.S. , Rueil-Malmaison Cedex , France ;
FAU - Benjamin, Laure
AU  - Benjamin L
AD  - f GlaxoSmithKline , Marly le Roi Cedex , France.
LA  - eng
PT  - Journal Article
DEP - 20160530
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/*economics/therapeutic use
MH  - Costs and Cost Analysis
MH  - Delphi Technique
MH  - Europe
MH  - Health Expenditures/statistics & numerical data
MH  - Health Services/economics/statistics & numerical data
MH  - Humans
MH  - Immunotherapy/*adverse effects/*economics
MH  - Melanoma/pathology/*therapy
MH  - Neoplasm Metastasis
MH  - Skin Neoplasms/pathology/*therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Australia
OT  - Cost burden
OT  - Direct medical costs
OT  - Europe
OT  - Medical resource utilization
OT  - Metastatic melanoma
EDAT- 2016/04/29 06:00
MHDA- 2017/06/27 06:00
CRDT- 2016/04/29 06:00
PHST- 2016/04/29 06:00 [entrez]
PHST- 2016/04/29 06:00 [pubmed]
PHST- 2017/06/27 06:00 [medline]
AID - 10.1080/13696998.2016.1184155 [doi]
PST - ppublish
SO  - J Med Econ. 2016 Sep;19(9):900-12. doi: 10.1080/13696998.2016.1184155. Epub 2016 
      May 30.